The amplification and oncogenic mutations of HER2 in lung cancer promote hyperactivation of downstream PI3K–AKT and MEK–ERK/MAPK pathways, promoting carcinogenesis (13, 14). This evidence concerns the gene ERBB2 and lung cancer.